Patient-Derived Organoids Predict Responses to Chemotherapy and PARP Inhibitors in Advanced Ovarian Cancer

Patient-derived organoids were established from treatment-naive epithelial ovarian cancer specimens and characterized by H&E staining, immunohistochemistry, and whole-exome sequencing.